Development of the epidermal growth factor receptor inhibitor OSI-774
- PMID: 12802792
- DOI: 10.1016/s0093-7754(03)70022-0
Development of the epidermal growth factor receptor inhibitor OSI-774
Abstract
The epidermal growth factor receptor (EGFR) is a transmembrane receptor involved in the regulation of a complex array of essential biological processes such as cell proliferation and survival. Dysregulation of the EGFR signaling network has been frequently reported in multiple human cancers and has been associated with the processes of tumor development, growth, proliferation, metastasis, and angiogenesis. Inhibition of the EGFR was associated with antitumor effects in preclinical models. On the basis of these data, therapeutics targeting the EGFR were explored in clinical trials. OSI-774 is a small-molecule selective inhibitor of the EGFR tyrosine kinase. In preclinical studies, OSI-774 inhibited the phosphorylation of the EGFR in a dose-dependent and concentration-dependent manner resulting in cell cycle arrest and induction of apoptosis. In in vivo studies, this agent caused tumor growth inhibition and showed synergistic effects when combined with conventional chemotherapy. Subsequent single-agent phase I studies and phase I studies in combination with chemotherapy showed that the agent has a good safety profile and induced tumor growth inhibition in a substantial number of patients with a variety of different solid tumors. Preliminary reports from phase II studies confirmed the excellent tolerability of OSI-774 and showed encouraging preliminary activity. Phase III studies have either been completed or are ongoing in several tumor types such as lung cancer and pancreatic cancer. In summary, OSI-774 is a novel inhibitor of the EGFR tyrosine kinase that has shown promising activity in initial studies and is currently undergoing full development as an anticancer drug.
Copyright 2003 Elsevier Inc. All rights reserved.
Similar articles
-
Role of tyrosine kinase inhibitors in lung cancer.Anticancer Agents Med Chem. 2009 Jun;9(5):569-75. doi: 10.2174/187152009788451879. Anticancer Agents Med Chem. 2009. PMID: 19519298
-
Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials.Expert Opin Emerg Drugs. 2003 Nov;8(2):501-14. doi: 10.1517/14728214.8.2.501. Expert Opin Emerg Drugs. 2003. PMID: 14662002 Review.
-
Development of the epidermal growth factor receptor inhibitor Tarceva (OSI-774).Adv Exp Med Biol. 2003;532:235-46. doi: 10.1007/978-1-4615-0081-0_19. Adv Exp Med Biol. 2003. PMID: 12908562 Review.
-
Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.Drugs R D. 2003;4(4):243-8. doi: 10.2165/00126839-200304040-00006. Drugs R D. 2003. PMID: 12848590
-
Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839.Semin Oncol. 2001 Oct;28(5 Suppl 16):56-66. doi: 10.1016/s0093-7754(01)90283-0. Semin Oncol. 2001. PMID: 11706397 Review.
Cited by
-
Validation of an MD simulation approach for electrical field responsive micelles and their application in drug delivery.Sci Rep. 2023 Feb 15;13(1):2665. doi: 10.1038/s41598-023-29835-y. Sci Rep. 2023. PMID: 36792790 Free PMC article.
-
Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer.JCO Precis Oncol. 2020 Oct 28;4:PO.20.00200. doi: 10.1200/PO.20.00200. eCollection 2020. JCO Precis Oncol. 2020. PMID: 33154984 Free PMC article.
-
Epidermal growth factor receptor first generation tyrosine-kinase inhibitors.Transl Lung Cancer Res. 2019 Nov;8(Suppl 3):S235-S246. doi: 10.21037/tlcr.2019.04.20. Transl Lung Cancer Res. 2019. PMID: 31857948 Free PMC article. Review.
-
Single-cell genetic analysis of clonal dynamics in colorectal adenomas indicates CDX2 gain as a predictor of recurrence.Int J Cancer. 2019 Apr 1;144(7):1561-1573. doi: 10.1002/ijc.31869. Epub 2018 Dec 11. Int J Cancer. 2019. PMID: 30229897 Free PMC article.
-
Advances in treating glioblastoma.F1000Prime Rep. 2014 Jun 2;6:46. doi: 10.12703/P6-46. eCollection 2014. F1000Prime Rep. 2014. PMID: 24991423 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous